Your browser doesn't support javascript.
loading
Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.
Cuzick, Jack M; Stone, Steven; Lenz, Lauren; Flake, Darl D; Rajamani, Saradha; Moller, Henrik; Berney, Daniel Maurice; Cohen, Todd; Scardino, Peter T.
Afiliação
  • Cuzick JM; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
  • Stone S; Myriad Genetics, Inc., Salt Lake City, Utah, USA.
  • Lenz L; Myriad Genetics, Inc., Salt Lake City, Utah, USA.
  • Flake DD; Myriad Genetics, Inc., Salt Lake City, Utah, USA.
  • Rajamani S; Myriad Genetics, Inc., Salt Lake City, Utah, USA.
  • Moller H; Department of Cancer Epidemiology, Population and Global Health, King's College London, London, UK.
  • Berney DM; Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Cohen T; Myriad Genetics, Inc., Salt Lake City, Utah, USA.
  • Scardino PT; Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Cancer Rep (Hoboken) ; 5(8): e1535, 2022 08.
Article em En | MEDLINE | ID: mdl-34423592

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Ressecção Transuretral da Próstata Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Rep (Hoboken) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Ressecção Transuretral da Próstata Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Rep (Hoboken) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido